

Victor Moreno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/526061/publications.pdf>

Version: 2024-02-01

58
papers

5,405
citations

186209

28
h-index

143943

57
g-index

59
all docs

59
docs citations

59
times ranked

8420
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	13.9	997
2	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
3	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
4	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2019, 20, 1124-1135.	5.1	339
5	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan- <i>Fibroblast Growth Factor Receptor</i> Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3401-3408.	0.8	324
6	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2 ³ , randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	5.1	288
7	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	5.1	247
8	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	0.5	241
9	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	3.2	181
10	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	0.5	181
11	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3002.	0.8	129
12	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	1.4	126
13	Risk excess of soft-tissue sarcoma and thyroid cancer in a community exposed to airborne organochlorinated compound mixtures with a high hexachlorobenzene content. <i>International Journal of Cancer</i> , 1994, 56, 200-203.	2.3	116
14	Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. <i>Oncologist</i> , 2015, 20, 127-133.	1.9	109
15	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVD). <i>European Journal of Cancer</i> , 2020, 137, 272-284.	1.3	86
16	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
17	Standardized Approach for Microsatellite Instability Detection in Colorectal Carcinomas. <i>Journal of the National Cancer Institute</i> , 2000, 92, 544-549.	3.0	75
18	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	3.4	68

#	ARTICLE	IF	CITATIONS
19	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	3.2	67
20	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. <i>European Journal of Cancer</i> , 2018, 89, 56-63.	1.3	60
21	Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. <i>Journal of Clinical Oncology</i> , 2017, 35, 8503-8503.	0.8	60
22	A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 12-12.	0.8	59
23	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 460-472.	3.2	48
24	Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2020, 31, 780-788.	0.6	42
25	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer and in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 474-484.	1.0	41
26	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4511-4520.	3.2	39
27	A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. <i>European Journal of Cancer</i> , 2017, 87, 131-139.	1.3	35
28	Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. <i>European Journal of Cancer</i> , 2021, 146, 135-144.	1.3	33
29	Safety and Antitumor Activity of ±PD-L1 Antibody as Monotherapy or in Combination with ±TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 6393-6404.	3.2	29
30	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100418.	1.5	29
31	T-cell-engaging Therapy for Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1595-1603.	3.2	21
32	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 438-446.	3.2	21
33	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S393-S394.	0.5	20
34	Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond. <i>Current Opinion in Pharmacology</i> , 2021, 59, 70-84.	1.7	18
35	PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study. <i>Journal of Clinical Oncology</i> , 2018, 36, 5565-5565.	0.8	18
36	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020, 6, 1357-1362.	0.8	16

#	ARTICLE	IF	CITATIONS
37	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. <i>Clinical Cancer Research</i> , 2022, 28, 1285-1293.	3.2	16
38	Increased vulnerability of clinical research units during the COVID-19 crisis and their protection. <i>Cancer</i> , 2020, 126, 3907-3911.	2.0	10
39	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 391-398.	2.9	10
40	Clinical activity of CC-90011 , an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. <i>Cancer</i> , 2022, 128, 3185-3195.	2.0	10
41	Dostarlimab for the treatment of endometrium cancer and other solid tumors. <i>Drugs of Today</i> , 2021, 57, 187.	0.7	9
42	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. <i>Lung Cancer</i> , 2021, 155, 151-155.	0.9	9
43	Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era. <i>Clinical Cancer Research</i> , 2021, 27, 2669-2671.	3.2	8
44	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	1.1	7
45	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1099-1109.	1.0	6
46	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	2.0	6
47	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	0.7	6
48	Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. <i>Drugs of Today</i> , 2019, 55, 485.	0.7	6
49	G1TR Antibodies in Cancer: Not Ready for Prime Time. <i>Clinical Cancer Research</i> , 2022, 28, 3905-3907.	3.2	6
50	Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. <i>Clinical Therapeutics</i> , 2021, 43, 1092-1111.	1.1	5
51	Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2985-2998.	2.0	5
52	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19447-19457.	1.8	3
53	Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891. <i>Annals of Oncology</i> , 2018, 29, viii144.	0.6	3
54	Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma. <i>Annals of Oncology</i> , 2019, 30, v523-v524.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2574-2574.	0.8	2
56	Anti-drug antibodies in the current management of cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 577-584.	1.1	2
57	Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer. Annals of Oncology, 2019, 30, v715-v716.	0.6	1
58	Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab). Archives of Clinical and Medical Case Reports, 2019, 04, .	0.0	0